RD162 ( RD 162;RD-162 )

Catalog No. M16572 CAS No. 915087-27-3

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Group Booking Get Quotation Bulk Inquiry Add to Cart

Product Name

RD162
Note

Research use only, not for human use.
Brief Description

RD162 is a second-generation, orally available antiandrogen that binds to androgen receptor (AR) with IC50 of 30.9 nM.
Description

RD162 is a second-generation, orally available antiandrogen that binds to androgen receptor (AR) with IC50 of 30.9 nM; suppresses growth and induces apoptosis in human prostate cancer cells in vitro, demonstrates greater relative affinity than the clinically used antiandrogen bicalutamide, reduces the efficiency of its nuclear translocation, and impairs both DNA binding to androgen response elements and recruitment of coactivators; induces tumor regression in mouse models of castration-resistant human prostate cancer.
Synonyms

RD 162;RD-162
Pathway

Endocrinology/Hormones
Target

Androgen Receptor (AR)
Recptor

Androgen Receptor (AR)
Research Area

Neurological Disease
Indication

——

CAS Number

915087-27-3
Formula Weight

476.45
Molecular Formula

C22H16F4N4O2S
Purity

>98% (HPLC)
Solubility

——
SMILES

CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(C=C4)C#N)C(F)(F)F)F
Chemical Name

4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide

1. Tran C, et al. Science. 2009 May 8;324(5928):787-90.
2. Makkonen H, et al. Mol Cell Endocrinol. 2011 Jan 1;331(1):57-65.

Calculator

molnova catalog